Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new class of blood thinner just got the green light. The FDA has approved asundexian (Sunharbo), the first factor XIa inhibitor, for secondary stroke prevention in adults with recent noncardioembolic ischemic stroke or high-risk TIA. It cuts recurrent stroke risk without significantly raising bleeding risk — but at $748.50/month list price, cost could be a major hurdle to widespread adoption.
The FDA has approved asundexian (Sunharbo), marking the debut of an entirely new class of oral anticoagulants — factor XIa inhibitors. Made by Bayer, the drug is indicated for adults with a recent noncardioembolic ischemic stroke (NIHSS ≤15) or high-risk TIA who are already on antiplatelet therapy. It is not approved for patients with atrial fibrillation.
The approval is backed by the OCEANIC-STROKE trial (12,327 patients), which showed asundexian 50 mg once daily reduced recurrent ischemic stroke by a relative 26% and absolute 2.2% over two years — with no significant increase in major bleeding. Subanalyses confirmed consistent benefits across vascular risk levels, meaning clinicians won't need to calculate a risk score before prescribing.
Why it matters: Asundexian offers a long-awaited tool for a population with few options — delivering meaningful stroke protection without the bleeding trade-off that has historically constrained antithrombotic therapy. However, its high list price and the need for physician education and insurance coverage pathways could slow real-world uptake, particularly in the near term.
